|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
|
WO2003048197A1
(en)
*
|
2001-12-07 |
2003-06-12 |
Crucell Holland B.V. |
Production and of viruses, viral isolates and vaccines
|
|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
WO2003050286A1
(en)
*
|
2001-10-29 |
2003-06-19 |
Crucell Holland B.V. |
Methods and means for producing proteins with predetermined post-translational modifications
|
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7527961B2
(en)
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7425437B2
(en)
*
|
1999-11-26 |
2008-09-16 |
Crucell Holland B.V. |
Vaccines against West Nile Virus
|
|
US7521220B2
(en)
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
|
EP1256803A1
(en)
*
|
2001-05-07 |
2002-11-13 |
Crucell Holland B.V. |
Methods for the identification of antiviral compounds
|
|
CA2756610C
(en)
|
2001-10-29 |
2015-08-25 |
Crucell Holland B.V. |
Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
|
|
KR100979025B1
(ko)
*
|
2001-12-07 |
2010-08-30 |
크루셀 홀란드 비.브이. |
바이러스, 바이러스 단리물 및 백신의 생산
|
|
WO2003051927A2
(en)
*
|
2001-12-17 |
2003-06-26 |
Crucell Holland B.V. |
Production of f(ab')2 fragments in mammalian cells
|
|
KR100454016B1
(ko)
*
|
2002-01-05 |
2004-10-26 |
한국과학기술원 |
항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
|
|
EP1471930B1
(en)
*
|
2002-01-09 |
2007-04-11 |
Crucell Holland B.V. |
Use of erythropoietin for the preventive or curative treatment of cardiac failure
|
|
US8287864B2
(en)
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
KR101033196B1
(ko)
|
2002-02-14 |
2011-05-09 |
이뮤노메딕스, 인코오포레이티드 |
항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
|
|
US7282567B2
(en)
|
2002-06-14 |
2007-10-16 |
Immunomedics, Inc. |
Monoclonal antibody hPAM4
|
|
KR101017732B1
(ko)
|
2002-03-01 |
2011-02-28 |
이뮤노메딕스, 인코오포레이티드 |
내재화 항-ｃｄ74 항체 및 그 이용방법
|
|
AU2002307635A1
(en)
*
|
2002-04-19 |
2003-11-03 |
Crucell Holland B.V. |
Methods and means for producing proteins with predetermined post-translational modifications
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
CA2494310A1
(en)
|
2002-08-01 |
2004-02-12 |
Immunomedics, Inc. |
Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
|
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
|
US8524477B2
(en)
|
2002-10-29 |
2013-09-03 |
Crucell Holland B.V. |
Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
CN100383238C
(zh)
*
|
2003-05-09 |
2008-04-23 |
克鲁塞尔荷兰公司 |
E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
|
|
EP1626992B1
(en)
*
|
2003-05-23 |
2010-06-02 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
|
NZ543635A
(en)
|
2003-06-25 |
2008-05-30 |
Crucell Holland Bv |
Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
|
|
EP2216342B1
(en)
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
EP1508576A1
(en)
*
|
2003-08-20 |
2005-02-23 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
HRP20130616T1
(en)
|
2003-10-02 |
2013-08-31 |
Crucell Holland B.V. |
Packaging cells for recombinant adenovirus
|
|
WO2005059149A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Chromagenics B.V. |
Improved protein production
|
|
DK1737971T3
(da)
|
2004-01-20 |
2017-11-13 |
Merus Nv |
Blandinger af bindingsproteiner
|
|
CA2557046A1
(en)
|
2004-03-05 |
2005-10-13 |
John Crowley |
Process for cell culturing by continuous perfusion and alternating tangential flow
|
|
CN1961002B
(zh)
|
2004-05-27 |
2011-05-18 |
克鲁塞尔荷兰公司 |
能中和狂犬病病毒的结合分子及其应用
|
|
WO2006040322A1
(en)
|
2004-10-12 |
2006-04-20 |
Crucell Holland B.V. |
Binding molecules for treatment and detection of cancer
|
|
EP1809750B1
(en)
|
2004-11-08 |
2012-03-21 |
ChromaGenics B.V. |
Selection of host cells expressing protein at high levels
|
|
EP1812067B1
(en)
|
2004-11-11 |
2012-03-21 |
Crucell Holland B.V. |
Compositions against sars-coronavirus and uses thereof
|
|
CA2591665C
(en)
|
2004-12-20 |
2015-05-05 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing west nile virus and uses thereof
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
AU2006245734C1
(en)
|
2005-05-12 |
2012-05-24 |
Crucell Holland B.V. |
Host cell specific binding molecules capable of neutralizing viruses and uses thereof
|
|
EP1739179A1
(en)
*
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
|
US20080206246A1
(en)
*
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
US8470318B2
(en)
|
2005-11-07 |
2013-06-25 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
US20080286819A1
(en)
*
|
2005-11-07 |
2008-11-20 |
Ravetch Jeffrey V |
Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
|
|
AR053416A1
(es)
|
2005-11-10 |
2007-05-09 |
Protech Pharma S A |
Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
|
|
DE102005054628A1
(de)
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
US7642078B2
(en)
|
2005-12-28 |
2010-01-05 |
Crucell Holland B.V. |
Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
|
|
US7968700B2
(en)
|
2006-03-20 |
2011-06-28 |
Chromagenics B.V. |
Expression augmenting DNA fragments, use thereof, and methods for finding thereof
|
|
MX2008012843A
(es)
*
|
2006-04-05 |
2009-01-19 |
Univ Rockefeller |
Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
|
|
WO2007141274A2
(en)
|
2006-06-06 |
2007-12-13 |
Crucell Holland B.V. |
Human binding molecules having killing activity against staphylococci and uses thereof
|
|
US7960518B2
(en)
|
2006-06-06 |
2011-06-14 |
Crucell Holland B.V. |
Human binding molecules having killing activity against enterococci and uses thereof
|
|
SI2041259T1
(sl)
|
2006-07-14 |
2016-04-29 |
Dpx Holdings B.V. |
Izboljšan postopek kultiviranja celic
|
|
NZ574581A
(en)
|
2006-09-07 |
2012-02-24 |
Crucell Holland Bv |
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
|
|
JP5161882B2
(ja)
|
2006-09-07 |
2013-03-13 |
クルセル ホランド ベー ヴェー |
インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
|
|
CA2666308C
(en)
*
|
2006-10-26 |
2014-09-23 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
EP2091969A4
(en)
*
|
2006-10-27 |
2010-05-12 |
Univ Rockefeller |
POLYPEPTIDES WITH IMPROVED INFLAMMATORY INHIBITION AND REDUCED CYTOTOXIC PROPERTIES AND RELATED METHODS THEREFOR
|
|
EP3176263A1
(en)
|
2007-08-10 |
2017-06-07 |
Toto Ltd. |
Method of producing recombinant mammalian cells
|
|
EP2222694B1
(en)
*
|
2007-12-13 |
2014-01-15 |
Roche Diagnostics GmbH |
Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
|
|
WO2009126308A2
(en)
*
|
2008-04-11 |
2009-10-15 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for vaccine and virus production
|
|
WO2009132130A2
(en)
|
2008-04-22 |
2009-10-29 |
The Rockefeller University |
Methods of identifying anti-inflammatory compounds
|
|
CN102216449B
(zh)
*
|
2008-07-15 |
2013-03-06 |
克鲁塞尔荷兰公司 |
用于培养per.c6细胞以及从中生产产物的可规模化的方法
|
|
JP6049163B2
(ja)
|
2008-07-21 |
2016-12-21 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
改善された治療上の特徴のための抗体の構造変異体
|
|
AU2010244592B2
(en)
|
2009-04-23 |
2016-05-19 |
Janssen Vaccines & Prevention B.V. |
Recombinant human alpha1-antitrypsin
|
|
AU2010247530B2
(en)
|
2009-05-11 |
2016-10-13 |
Janssen Vaccines & Prevention B.V. |
Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
|
|
EP2484761A4
(en)
|
2009-10-01 |
2013-11-27 |
Toto Ltd |
DNA CONSTRUCT AND METHOD FOR PRODUCING RECOMBINANT CHO CELLS THEREWITH
|
|
SI2501817T2
(sl)
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
DK2731967T3
(en)
|
2011-07-14 |
2017-01-16 |
Janssen Vaccines & Prevention Bv |
HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS
|
|
RS59728B1
(sr)
|
2011-08-05 |
2020-02-28 |
Regeneron Pharma |
Humanizovani miševi univerzalnog lakog lanca
|
|
WO2013093760A2
(en)
|
2011-12-19 |
2013-06-27 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
CN102827273A
(zh)
*
|
2012-02-16 |
2012-12-19 |
张小莺 |
抗痘苗病毒IgY抗体的制备
|
|
AU2013229488B2
(en)
|
2012-03-08 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
|
|
SI2838917T1
(sl)
|
2012-04-20 |
2019-11-29 |
Merus Nv |
Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
|
|
US9657290B2
(en)
*
|
2012-07-03 |
2017-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Scalable bio-element analysis
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
JP2016504015A
(ja)
|
2012-09-27 |
2016-02-12 |
クルセル ホランド ベー ヴェー |
Ｂ型肝炎ウイルスに結合し、かつ中和することができるヒト結合分子およびその使用
|
|
EP3470431A1
(en)
|
2012-09-27 |
2019-04-17 |
Merus N.V. |
Bispecific igg antibodies as t cell engagers
|
|
WO2014170257A1
(en)
|
2013-04-15 |
2014-10-23 |
Crucell Holland B.V. |
Human antibodies binding to rsv g protein
|
|
EA035846B1
(ru)
|
2013-04-15 |
2020-08-20 |
Янссен Вэксинс Энд Превеншн Б.В. |
Антитела человека, связывающиеся с g-белком rsv
|
|
DE112014003136A5
(de)
|
2013-07-01 |
2016-04-21 |
Charité - Universitätsmedizin Berlin |
Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen
|
|
CN104693308B
(zh)
*
|
2013-12-05 |
2020-08-04 |
同济大学 |
感受胞内pH变化的Smad5蛋白及其应用
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
EP3786186A1
(en)
|
2014-02-28 |
2021-03-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
IL301147A
(en)
|
2014-02-28 |
2023-05-01 |
Merus Nv |
An antibody that binds to ErbB-2 and ErbB-3
|
|
KR102276752B1
(ko)
|
2014-03-21 |
2021-07-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
TW202204596A
(zh)
|
2014-06-06 |
2022-02-01 |
美商健臻公司 |
灌注培養方法及其用途
|
|
WO2016124682A1
(en)
|
2015-02-05 |
2016-08-11 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza neuraminidase
|
|
EA038407B1
(ru)
|
2015-02-05 |
2021-08-24 |
Янссен Вэксинс Энд Превеншн Б.В. |
Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
|
|
CN107532333A
(zh)
|
2015-02-22 |
2018-01-02 |
里兰斯坦福初级大学理事会 |
微筛选装置、方法和产品
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
SI3115376T1
(sl)
|
2015-07-10 |
2018-12-31 |
Merus N.V. |
Humana protitelesa, ki vežejo CD3
|
|
CA3002957A1
(en)
|
2015-10-23 |
2017-04-27 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Binding molecules that inhibit cancer growth
|
|
US10703803B2
(en)
|
2016-03-01 |
2020-07-07 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza B neuraminidase
|
|
CN115254210A
(zh)
|
2016-11-14 |
2022-11-01 |
浩康生物系统公司 |
用于分选目标颗粒的方法和装置
|
|
WO2018178077A1
(en)
|
2017-03-28 |
2018-10-04 |
Janssen Vaccines & Prevention B.V. |
Binding molecules that specifically bind to tau
|
|
AU2018246873B2
(en)
|
2017-03-31 |
2021-05-06 |
Merus B.V. |
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
|
|
EP3612648A1
(en)
|
2017-04-18 |
2020-02-26 |
Université Libre de Bruxelles |
Biomarkers and targets for proliferative diseases
|
|
WO2018212656A1
(en)
|
2017-05-17 |
2018-11-22 |
Merus N.V. |
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
|
|
CN118580366A
(zh)
|
2017-08-09 |
2024-09-03 |
美勒斯公司 |
结合EGFR和cMET的抗体
|
|
EP3693013A4
(en)
|
2017-10-06 |
2021-06-30 |
Ono Pharmaceutical Co., Ltd. |
BISPECIFIC ANTIBODY
|
|
WO2019110571A1
(en)
|
2017-12-04 |
2019-06-13 |
Janssen Vaccines & Prevention B.V. |
Binding molecules that specifically bind to tau
|
|
KR20200116105A
(ko)
|
2018-02-01 |
2020-10-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
타우에 특이적으로 결합하는 결합 분자
|
|
TWI849895B
(zh)
|
2018-02-09 |
2024-07-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
EP3768701B1
(en)
|
2018-03-23 |
2023-08-02 |
Université Libre de Bruxelles |
Wnt signaling agonist molecules
|
|
TWI862565B
(zh)
|
2019-04-04 |
2024-11-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
WO2021020416A1
(ja)
|
2019-07-30 |
2021-02-04 |
小野薬品工業株式会社 |
二重特異性抗体
|
|
EP4011918A4
(en)
|
2019-08-08 |
2023-08-23 |
ONO Pharmaceutical Co., Ltd. |
DUAL SPECIFIC PROTEIN
|
|
BR112023025520A2
(pt)
*
|
2021-06-11 |
2024-02-27 |
Monsanto Technology Llc |
Métodos e composições para alteração do acúmulo de proteínas
|
|
WO2024043227A1
(ja)
|
2022-08-23 |
2024-02-29 |
小野薬品工業株式会社 |
二重特異性抗体
|
|
WO2026068859A1
(en)
|
2024-09-30 |
2026-04-02 |
Université Libre de Bruxelles |
Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
|